Human atheromata obtained in vivo were used to test the hypothesis that transforming growth factor-(31 plays a role in the development of vascular restenosis.
Introduction
Cell division and migration ofvascular smooth muscle cells are controlled by a network of interacting growth factors and receptors. It is widely accepted that smooth muscle cell proliferation is responsible for generation ofrestenotic lesions in vascular tissue (1) (2) (3) (4) (5) . Although restenosis complicates balloon angioplasty in at least 40% of cases, identification of the events and specific factors responsible for restenosis remains elusive. (12, 17) , and insulin-like growth factor-l ( 18) .
The target of our investigation was TGF-,31, the originally described and generally most abundant isoform of TGF-3 ( 19) . Its cDNA has been cloned and its primary structure is well studied. It is a multifunctional peptide growth factor with a molecular weight of 25,000 in the configuration of a homodimer (20) . In certain cell lines (21) (22) (23) (24) , TGF-i1 has been shown to bind preferentially to the TGF-f3 type III receptor (25, 26) , although the signal transducing receptor for TGF-,3 is likely one of the low molecular weight receptors. TGF-#3I controls growth and differentiation of a wide spectrum of normal and neoplastic cells. For some mesenchymal cells, TGF-# 1 has been found to be mitogenic in vitro and to stimulate wound healing in vivo (27) . In contrast, TGF-#3I has been shown to inhibit proliferation ofendothelial cells (28) (29) (30) , certain mitogenically stimulated B and T lymphocytes (31) (32) (33) , as well as normal and tumor-derived epithelial cells (34) (35) (36) , and to retard epithelial wound healing in vitro ( 12) .
TGF-#3I has also been reported to alternatively promote or inhibit growth, depending on cell age, cell density, the presence of coexistent factors (37) (38) (39) , and the concentration of TGFfl ( 13, 19, 40) . TGF-f3I can cause hypertrophy of smooth muscle cells, such as that resulting from systemic hypertension (37) , as well as stimulate production ofelastin (41 ) and proteoglycan (42) , both of which are common features ofatherosclerotic plaque.
Finally, the interaction of TGF-,3l with other growth factors is fundamental to the issue of thrombus formation, and dissolution. Specifically, basic fibroblast growth factor stimulates the production oftissue plasminogen activatorby endothelial cells (43), whereas TGF-# I inhibits release of tissue plasminogen activator mediated by basic FGF (37) .
While the results of these in vitro experiments suggested variable, including at times contradictory, functions for TGFf(1, three in vivo experiments yielded concordant findings regarding the role of TGF-# 1 in the repair of arterial injury. Madri et al. (44) , using the balloon-injured rat carotid artery model, found that at 10 wk after injury, the neointima of such arteries displayed increased staining of TGF-# 
Methods
Patients. Atherosclerotic tissue specimens were obtained from 28 patients with coronary artery or peripheral vascular disease. 14 of these specimens were obtained from patients with no history ofpercutaneous revascularization and were therefore classified as primary. The remaining 14 lesions were obtained from sites previously treated by balloon angioplasty and were therefore classified as restenosis lesions. For restenosis lesions, average time from previous angioplasty to current tissue retrieval was 7.50±6.19 mo. In addition to the atherosclerotic tissue specimens, seven control tissues including myocardium, normal internal mammary artery, and unused portions of saphenous vein were retrieved intraoperatively. The source of each tissue specimen is listed in Table I .
Tissue retrieval. In 26 of 28 patients, atherosclerotic specimens were retrieved by directional atherectomy using the Simpson AtheroCath (Devices for Vascular Intervention, Redwood City, CA) according to previously described techniques (46, 47) . In the two remaining patients, atherosclerotic specimens were obtained at the time of coronary artery bypass surgery.
Tissue preparation. For both in situ hybridization (ISH) and immunohistochemistry (IHC), tissues were immersed in ice-cold 4% paraformaldehyde (Fisher Scientific Co., Pittsburgh, PA) for 2 h within minutes after retrieval to minimize RNA degradation followed by immersion in 30% sucrose/PBS (Fisher) overnight at 40C. After embedding in O.C.T. compound (Miles Scientific Div., Miles Laboratories, Inc., Elkhart, IN), tissues were snap frozen in liquid nitrogen, stored at -70'C and finally sectioned on a cryostat (Miles) into 7-gm thick sections. Sections for ISH were placed on glass slides which had been previously coated with gelatin-chromic alum and incubated at 420C overnight. Slides for IHC were placed on poly-L-lysine coated glass slides and stored at -70'C.
Cell culture. Human smooth muscle cell cultures were initiated by outgrowth from explants of internal mammary artery retrieved during (8) 1 (4) 3 (12) 1 (4) 1 (4) 2 (11) 11 (47) coronary artery bypass surgery. Identification of smooth muscle cells was confirmed by positive immunostaining for a-smooth muscle actin (Sigma Chemical Co., St. Louis, MO) and lack of staining for Factor VIII-related antigen (Signet Laboratories, Dedham, MA). Cells at the third passage were seeded onto fibronectin-coated slides ( 10 jg/cm2) at a density of 3,000 cells per cm2 and allowed to grow for three days in medium 199 supplemented with 10% fetal bovine serum (Gibco Laboratories, Grand Island, NY). They were then fixed in 4% paraformaldehyde for 6 min and stored at -70'C before the hybridization procedure.
Preparation ofprobes. Freeze-dried Escherichia coli HB1O1 containing a plasmid with the insert encoding the complete coding sequence of human TGF-#31 (48) and human TGF-a (49) were obtained from the American Type Culture Collection (Rockville, MD).
The A-isoform of human nonmuscle myosin heavy chain is apparently present in all cells and presumably required for normal cell function (50) . As such it may be considered as a "housekeeping" gene; previous studies in our laboratory have specifically disclosed no differences in expression in cells from primary versus restenosis lesions (50) . The plasmid containing the 1.0-kb 3'-end of nonmuscle myosin heavy chain isoform A (NMMHC-A), kindly provided by Dr. Leslie Leinwand (Albert Einstein College of Medicine, Bronx, NY) (51), was therefore used as a "control" gene.
TGF-#31 is only -70% similar in sequence to TGF-#s 2 and 3, both of which have separate genes on separate chromosomes, as well as different promoter structures and regulatory elements (52) . After preparation of the plasmid, the 700-bp EcoRI/PstI fragment of TGF-f31, encoding the 3'-end of the insert, was isolated and subcloned into the polylinker of pGEM-3Zf(-) vector (Promega Corp., Madison, WI).
Similarly the 930-bp EcoRI fragment of TGF-a and the 1.0-kb EcoRI/PstI fragment of NMMHC-A were subcloned into pGEM3Zf (-).
TGF-f2 is a 1.25-kb SmaI fragment in pBluescript KSII+ and TGF-,3 is a 1.23-kb SmaI fragment in pBluescript KSII+ (53, 54) . Both were a generous gift of Drs. Denhez and Sporn (National Cancer Institute, Bethesda, MD).
The human TGF-13 type III receptor cDNA probe was a generous gift of Drs. Lin and Lodish (Whitehead Institute, Cambridge, MA). It is a 4.5-kb EcoRI fragment in pBluescript SK- (25) .
All probes contain dual promoters, which were used to generate antisense and sense RNA transcripts, labeled with [35S]UTP (sp act: 1,300 Ci/mmol) (NEN Research Products, Boston, MA).
In situ hybridization. The technique for ISH used in this study was modified from that described previously (55) . Before hybridization, sections from the 35 tissue specimens indicated above were rehydrated in PBS and 0.1 M glycine/PBS (Fisher), and then serially incubated in 0.3% Triton X-100/PBS (Fisher); Proteinase K (Boehringer-Mannheim GmbH, Mannheim, Germany); 4% paraformaldehyde: 0.25% acetic anhydride in triethanolamine (0.1 M, pH 8.0) (Fisher); and finally equal parts of diionized formamide (Sigma) and 4X standard saline citrate (SSC = 0.15 M NaCl/0.0 15 M trisodium citrate).
Tissue sections and cultured cells, prepared as described above, were incubated with the cRNA probe (3 X 105 cpm of 35S-labeled probe/ 10 gl hybridization buffer) in a moist chamber for 16 h overnight at 42°C. Hybridization buffer consisted of 50% formamide, 2 x SSC, 10% dextran sulfate, 0.25% BSA, 0.25% Ficoll 400,0.25% polyvinylpyrolidone 360, 250 mM Tris pH 7.5, 0.5% sodium pyrophosphate, 0.5% SDS, 250 ug/ml denatured salmon sperm DNA, 200 jig/ml yeast tRNA, and 10 mM dithiothreitol (Fisher, Sigma, Boehringer).
After hybridization, tissues were washed with 4 x SSC, treated with 20 ,ug/ml ribonuclease A (RNase A) (Sigma) in 0.5 M NaCl/ 10 mM Tris, pH 8.0/1 mM EDTA to eliminate nonhybridized cRNA strands, and washed in 2 X SSC and 0.1 x SSC. After dehydration in 70, 95, and 100% alcohol containing ammonium acetate, autoradiography in Kodak NTB-2 emulsion (Eastman Kodak Co., Rochester, NY) was performed, developed after 7 d, and counterstained with hematoxylin and eosin.
Transforming Growth Factor-f31 and Restenosis 1583
Immunohistochemistry. A total of 11 of 35 specimens on which ISH had been performed were selected for IHC (Table I) . IHC was performed on adjacent sections. Frozen 7-,gm tissue sections, fixed in 4% paraformaldehyde, were evaluated with three primary antibodies.
A monoclonal murine antibody to smooth muscle a-actin (clone 1A4, Sigma) was used to identify smooth muscle cells. For detection of TGF-31, we used two different polyclonal rabbit antibodies, referred to as anti-LC and anti-CC (kindly provided by Drs. Flanders and Sporn, National Cancer Institute, Bethesda, MD). Both were raised to the peptide corresponding to the first 30 amino acids of mature TGF-( 1; in Bouin's-fixed paraffin sections (56, 57) , however, anti-LC recognizes intracellular protein, whereas anti-CC recognizes extracellular protein.
Because cross-reaction of anti-LC with TGF-(2 has been previously reported, similar cross-reactivity with other TGF-( isoforms cannot be ruled out with certainty (56) . Sections stained without antibody were used as negative controls.
All staining procedures were conducted at room temperature. After immersion in PBS, sections were blocked with 1.5% normal goat serum for anti-TGF-flI or with normal horse serum for anti-a-actin, incubated with IgG fractions of the antibody, washed extensively, and then incubated with biotinylated goat anti-rabbit for anti-TGF-#3I or with horse anti-mouse for anti-a-actin IgG and avidine-enzyme complex. Sections were stained with 3,3'-diaminobenzidine and hydrogen peroxide (Signet) and counterstained with hematoxylin only.
Tissue section analysis. All sections were examined by light microscopy under dark-field and bright-field conditions at various magnifications (4-500). In an attempt to identify cell types expressing TGF-Il in plaque, the in situ autoradiographed slides were counterstained with hematoxylin and eosin and examined by light microscopy at higher magnification. In some cases serial sections were processed for immunohistochemistry using anti-a-actin as a marker for smooth muscle cells. Unmanipulated serial sections were counterstained with both hematoxylin and eosin and elastic-trichrome.
Sections prepared for ISH were examined quantitatively by handcounting of silver grains overlying cell nuclei at a magnification of 500. For each specimen hybridized with the antisense probe, 20 nuclei were randomly chosen: only the silver grains overlying the cell nuclei were considered, to determine a grain-to-nucleus ratio. Sections with high background ( (Fig. 2, Table III) .
Expression of TGF-,Bl was consistently high in restenotic tissues (Figs. 3 and 4) and consistently low in primary atherosclerotic tissues, regardless ofthe source (coronary artery, coronary artery bypass graft, peripheral artery). The background for sense controls was on average more than one grain per nucleus, whereas the results obtained with antisense probes were consistently and significantly greater.
Messenger RNA for TGF-j32 was not expressed at detectable levels, either in vascular tissues or in cultured vascular smooth muscle cells. TGF-a, TGF-133, and TGF-# type III receptor mRNA were expressed at low levels in cultured vascular smooth muscle cells, but were undetectable in tissue specimens (data not shown). Expression of the housekeeping gene NMMHC-A was similar (P = ns) among specimens from nonatherosclerotic internal mammary arteries (13±2 grains/nucleus), primary atherosclerotic arteries (9±1 grains/nucleus), and restenotic tissues ( 11±3 grains/nucleus). All these additional gene probes were used on adjacent sections of tissue specimens previously used for TGF-j 1. Immunohistochemistry. Anti-a-actin was used in adjacent sections to identify smooth muscle cells for ISH as well as IHC. The media ofthe nonatherosclerotic internal mammary artery and most cells of the atherosclerotic tissues showed positive staining indicating high content of smooth muscle cells.
Tissues examined for TGF-#3I anti-LC and anti-CC showed positive staining in cells identified as smooth muscle cells by application of anti-a-actin to adjacent tissue sections (Fig. 5 ).
In paraformaldehyde-fixed sections, staining for TGF-13I protein occurs in a perinuclear distribution; as a result, staining for both antibodies of TGF-f31 was predominantly intracellular among tissues studied in the current investigation. This contrasts with results reported previously (56) for Bouin's-fixed tissues, in which TGF-# 1 has been recognized both intracellularly and extracellularly. There was again no difference, regardless of the source. Discussion TGF was first described in 1978 and originally termed "sarcoma growth factor" (58) . Its ability to both change the cellular morphology of tumor cells and facilitate growth of such cells in soft agar resulted in its being renamed "transforming growth factor" (59) . Subsequently it was learned that these dual functions in fact represented the combined action of the two factors known today as TGF-a and TGF-3 (60) . The latter was also found in many normal cells including liver, heart, brain, kidney, muscle, and platelets (27, 39, 61, 62) and has been shown to exist in at least five isoforms (37) . cDNA cloning has demonstrated that TGF-#3I has 70% sequence identity to isoforms 2 and 3 (52) . TGF-#31 acts through a unique receptor complex that has no known homology to other growth factor receptors, and is devoid oftyrosine kinase activity (27, 62) .
The existence ofseveral isoforms of TGF-#3I that act differently with a number ofTGF-,B receptor subtypes has been inferred to constitute a flexible system for the regulation of tissue growth and differentiation (63) . Among certain nonvascular cell lines, the TGF-j type III receptor has been observed as the preferential and most abundant receptor for TGF-#31 (21) (22) (23) (24) , although the receptor responsible for TGF-# 1 signal transduction may well be one of the two low molecular weight receptors.
The current study was designed to examine the expression of the isoform TGF-# 1. This isoform was chosen for three reasons: (a) TGF-,3 1 had been previously demonstrated in vascular smooth muscle cells (12) (13) (14) ; (b) it had been the most abundant ofthe five isoforms ( 19) ; and (c) its cDNA had been previously cloned (48 lutely conserved among several eucaryotic species, and is identical in man, monkeys, cows, pigs, and chickens (64), suggesting that any mutation might be detrimental or even lethal.
While the results of previous experiments performed in vitro have suggested variable mitogenic effects for TGF-f31 on cellular proliferation, in vivo studies reported from three independent laboratories ( 14, 44, 45) each yielded results pointing to a role for TGF-f 1 in repair, including restenosis, after vascular injury.
To determine whether the in vivo observations reported in these animal model studies could be shown to extend to vascular disease, including restenosis, in humans, we investigated human atheromata. Access to such tissues has been facilitated by the advent of percutaneous directional atherectomy (46, 47) . This particular device is unique among currently employed atherectomy instruments in that it retrieves tissue specimens essentially intact, sufficient to permit microscopic analyses (47) . This is particularly advantageous for certain contemporary techniques such as ISH and IHC, both ofwhich are less optimally performed on autopsy tissues due to the degradation of mRNA and loss of protein antigenicity, respectively.
The amount of tissue obtained by directional atherectomy is typically insufficient to detect mRNA by Northern blot. We have observed, however, that when the results ofin situ hybridization are clearly positive, silver grains are preferentially associated with the nuclei. We have used this phenomenon to develop a quantitative scheme for analyzing the results of ISH by directly counting the number of silver grains per cell nucleus. Results in the present study have thus been expressed as an average number of grains/nucleus.
All tissues studied in the current investigation were found to express mRNA for TGF-f13; furthermore, expression of TGF-fl1 in restenotic atherosclerotic tissues was significantly greater than that found in primary atherosclerotic tissue. Expression ofTGF-,B1 among cultures ofhuman vascular smooth muscle cells was consistent with these observations: mRNA expression was higher among subconfluent, actively proliferating cells, than in those cultures in which further cell growth was inhibited by development of confluence. These findings thus suggest a relationship between the level of mRNA expression and degree of proliferation of human vascular smooth muscle.
The results of ISH must be interpreted to indicate relative levels of mRNA abundance, and may thus reflect levels ofgene expression and/or stability of mRNA. The end result of the ISH procedure is a slide with dark silver grains in bright-field microscopy and white silver grains in dark-field microscopy, each ofwhich indicates the presence of labeled probe. Washing procedures and RNase treatment remove most nonspecific binding. Even controls performed with sense probes, however, which would not be expected to hybridize, show a small background level of sliver grains which may vary depending upon the particular probe employed and the tissue inspected. We determined that subtraction of the average number of background grains/nucleus was unnecessary, because the primary results achieved statistical significance. Subtraction of the background grains/nucleus, however, would only be expected to increase the described differences.
ISH with the housekeeping gene NMMHC-A as control gene revealed no significant difference among nonatherosclerotic, primary atherosclerotic, and restenotic tissue specimens. In contrast, the increased expression observed among specimens from restenotic versus primary tissues is consistent with the notion that such increased expression of TGF-#31 mRNA is related to smooth muscle cell proliferation. . ( 14) . Although TGF-f1 mRNA expression was significantly increased in restenotic tissues compared to primary and nonatherosclerotic tissues, and subconfluent cultures ofhuman vascular smooth muscle cells compared to confluent cells, these preliminary findings can only be interpreted to suggest, but not prove, a role for TGF-31 in the development of restenosis lesions. TGF-l1 has been previously reported to alternatively promote or inhibit growth, depending on cell age, cell density, the presence of coexisting factors (37, 38) , and the concentration of TGF-f I ( 13, 19, 40) . For example, TGF-f 1 inhibits the proliferation of smooth muscle cells in culture, but only at subconfluent densities, when proliferation is also mediated by PDGF (38) . In confluent cells, on the other hand, TGF-l1 promotes proliferation of smooth muscle cells (37) . The complex control ofan autocrine PDGF loop has been found responsible for the bimodal proliferation induced by TGF-ll in cultured smooth muscle cells, fibroblasts, and chondrocytes (40) . At low concentrations TGF-f 1 induces proliferation by stimulating PDGF-AA secretion, while at higher concentrations TGF-3 1 inhibits proliferation by downregulation ofthe PDGF receptor a subunit (40) . TGF-f3I also inhibits growth induced by fibroblast growth factor and epidermal growth factor in endothelial cells (28, 30, 37, 39) , and modulates the synthesis of growth factor receptors (37) .
Finally, it must be acknowledged that the presence of the TGF-f 1 receptors has not yet been demonstrated in atherosclerotic tissues. This contrasts with the published finding of such receptors in immune killer cells ( 19) , which, along with the finding of increased production of TGF-f 1, has been interpreted to indicate an autocrine function for TGF-,Bl in these cells. An autocrine function for TGF-3 1 in vascular smooth muscle cells of atherosclerotic lesions would predict the presence of TGF-j receptors in these cells. Accordingly, we also performed ISH with a probe for the recently cloned TGF-f type III receptor (25) , which is the preferential receptor for TGF-O3 1. In the current investigation, TGF-f type III receptor was detectable in cultured vascular smooth muscle cells at low levels, but in none ofthe tissue specimens. The proper interpretation of these findings remains uncertain, because cellular mechanisms of TGF-fs are still unknown (26) . It is possible that in vascular tissues, the type III receptor is not the preferred or predominant receptor for TGF-3 1. It is also possible that receptor preference for TGF-l1 may be altered under pathologic conditions, such as atherosclerosis and/or restenosis, and under such conditions TGF-f 1 may be overexpressed due to a nonresponding type III receptor; or finally, that TGF-f type III receptor mRNA may be present, but at levels too low to be detectable.
Further elucidation ofthese remaining questions, including whether TGF-f1 acts in an autocrine fashion, whether it has a primary role in governing vascular smooth muscle cell proliferation, and how it interacts with other growth factors implicated to play a role in restenosis, may 
